Private equity owners of the country’s leading IVF treatment platforms say they are getting educated on state laws and preparing for the aftermath of the June 24 Dobbs ruling, Axios reports. While Dobbs introduces a new layer of uncertainty in the near term, investors say interest in fertility remains robust with long-term industry tailwinds plentiful.
Fertility has always been a highly regulated industry, both around egg storage and outcomes reporting. But, with a cash- and commercial-payor base, fertility has historically been deemed lower-risk by many investors from a reimbursement and regulatory perspective. (In contrast, many other medical specialties depend on Medicare or Medicaid reimbursement.) Read more.
